Imprimis Pharmaceuticals (IMMY) Hits New 52-Week High at $4.80
Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)’s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $4.80 and last traded at $4.76, with a volume of 3373 shares trading hands. The stock had previously closed at $4.61.
The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 3.66.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its earnings results on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.03). Imprimis Pharmaceuticals had a negative net margin of 28.59% and a negative return on equity of 372.57%. The company had revenue of $10.74 million during the quarter.
Institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp grew its stake in Imprimis Pharmaceuticals by 145.8% in the first quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 39,750 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Imprimis Pharmaceuticals in the third quarter valued at about $259,000. Ardsley Advisory Partners grew its stake in Imprimis Pharmaceuticals by 42.9% in the second quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $220,000 after purchasing an additional 30,000 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Imprimis Pharmaceuticals by 104.3% in the third quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock worth $328,000 after acquiring an additional 60,248 shares in the last quarter. Finally, Granite Investment Partners LLC boosted its holdings in Imprimis Pharmaceuticals by 153.8% in the second quarter. Granite Investment Partners LLC now owns 170,962 shares of the specialty pharmaceutical company’s stock worth $376,000 after acquiring an additional 103,607 shares in the last quarter. Institutional investors own 8.65% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Imprimis Pharmaceuticals (IMMY) Hits New 52-Week High at $4.80” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://theolympiareport.com/2018/11/15/imprimis-pharmaceuticals-immy-hits-new-52-week-high-at-4-80.html.
Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.
Recommended Story: What is the quiet period?
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.